Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

被引：16

作者：

McCubrey, James A. ^{[1
]}

Sokolosky, Melissa L. ^{[1
]}

Lehmann, Brian D. ^{[1
]}

Taylor, Jackson R. ^{[1
]}

Navolanic, Patrick M. ^{[1
]}

Chappell, William H. ^{[1
]}

Abrams, Stephen L. ^{[1
]}

Stadelman, Kristin M. ^{[1
]}

Wong, Ellis W. T. ^{[1
]}

Misaghian, Negin ^{[1
]}

Horn, Stefan

Baesecke, Joerg

Libra, Massimo

Stivala, Franca

Ligresti, Giovanni

Tafuri, Agostino

Milella, Michele

Zarzycki, Marek

Dzugaj, Andrzej

Chiarini, Francesca

Evangelisti, Camilla

Martelli, Alberto M.

Terrian, David M. ^{[1
]}

Franklin, Richard A. ^{[1
]}

Steelman, Linda S. ^{[1
]}

机构：

[1] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA

来源：

ADVANCES IN ENZYME REGULATION, VOL 48 | 2008年 / 48卷

关键词：

D O I：

10.1016/j.advenzreg.2008.02.006

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Breast cancer is a common disease which affects women and men in the prime of their lives. Unfortunately there is no common magic bullet which can effectively cure all breast cancers. Breast cancer arises from many diverse genetic mechanisms. Frequently breast cancer becomes resistant to various therapies and residual, dormant, senescent, drug resistant breast cancer cells resume their growth and often metastasize to other sites. At this point, therapeutic options are limited and we desperately need more effective treatments. This chapter has focused on the key roles that the PI3K/PTEN/Akt/mTOR pathway plays in breast cancer drug resistance and induction of cellular sensecence. Furthermore, breast cancer cells which proliferate in response to this pathway may have an Achilles heel and are highly sensitive to mTOR inhibitors. © 2008 Elsevier Ltd. All rights reserved.

引用

页码：113 / +

页数：7

共 203 条

[1] Transient and sustained ERK phosphorylation and nuclear translocation in growth control [J].

Adachi, T ;

Kar, S ;

Wang, MF ;

Carr, BI .

JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 192 (02) :151-159

[2] Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK [J].

Allan, LA ;

Morrice, N ;

Brady, S ;

Magee, G ;

Pathak, S ;

Clarke, PR .

NATURE CELL BIOLOGY, 2003, 5 (07) :647-U45

[3] Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1 [J].

Aplin, AE ;

Stewart, SA ;

Assoian, RK ;

Juliano, RL .

JOURNAL OF CELL BIOLOGY, 2001, 153 (02) :273-281

[4]

Arcinas M, 2001, CANCER RES, V61, P5202

[5] Oncogenic PI3K deregulates transcription and translation [J].

Bader, AG ;

Kang, SY ;

Zhao, L ;

Vogt, PK .

NATURE REVIEWS CANCER, 2005, 5 (12) :921-929

[6]

Barnes G, 2005, Int J Surg, V3, P206, DOI 10.1016/j.ijsu.2005.04.001

[7] Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs [J].

Blagosklonny, MV .

LEUKEMIA, 2002, 16 (04) :455-462

[8] Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs [J].

Blalock, WL ;

Weinstein-Oppenheimer, C ;

Chang, F ;

Hoyle, PE ;

Wang, XY ;

Algate, PA ;

Franklin, RA ;

Oberhaus, SM ;

Steelman, LS ;

McCubrey, JA .

LEUKEMIA, 1999, 13 (08) :1109-1166

[9] Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia [J].

Blalock, WL ;

Navolanic, PM ;

Steelman, LS ;

Shelton, JG ;

Moye, PW ;

Lee, JT ;

Franklin, RA ;

Mirza, A ;

McMahon, M ;

White, MK ;

McCubrey, JA .

LEUKEMIA, 2003, 17 (06) :1058-1067

[10]

BROOKS SC, 1973, J BIOL CHEM, V248, P6251

← 1 2 3 4 5 6 7 8 9 10 →